from WSJ Live:
New drug trials for disorders like Down syndrome and Fragile X are presenting researchers with a dilemma: how to make sure people with intellectual disabilities consent to join. Amy Dockser Marcus and Massachusetts General Hospital's Brian Skotko discuss.
No comments:
Post a Comment